| Literature DB >> 17409216 |
M Schutten1, D Peters, N K T Back, M Beld, K Beuselinck, V Foulongne, A-M Geretti, L Pandiani, C Tiemann, H G M Niesters.
Abstract
The analytical performances of the new Abbott RealTime hepatitis C virus (HCV) and human immunodeficiency virus type 1 viral load assays were compared at nine laboratories with different competitor assays. These included the Abbott LcX, Bayer Versant bDNA, Roche COBAS Amplicor, and Roche COBAS TaqMan assays. Two different protocols used during the testing period with and without a pre-m1000 RNA isolation spin were compared. The difference proved to be nonsignificant. A uracil-N-glycosylase (UNG) contamination control option in the HCV test for previous Roche COBAS Amplicor users was evaluated. It proved to decrease amplicon carryover by 100-fold independent of the amplicon input concentration. The protocol including UNG proved to overcome problems with false-positive negative controls. Comparison with other assays revealed only minor differences. The largest difference was observed between the Abbott HCV RealTime assay and the Roche COBAS Amplicor HCV Monitor version 2.0 assay.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17409216 PMCID： PMC1933061 DOI： 10.1128/JCM.02385-06
Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948